Regulatory Aspects and Commercialization of Drug Products Containing Amorphous Solid Dispersions
- 2 July 2026
- book chapter
- Published by Springer Nature
- p. 345-360
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Modern approaches to quality by design for amorphous solid dispersion product development: a narrative reviewJournal of Pharmaceutical Investigation, 2026
- Enhanced Bioavailability and Reduced Variability of Dasatinib and Sorafenib with a Novel Amorphous Solid Dispersion Technology PlatformClinical Pharmacology in Drug Development, 2024
- The challenge of downstream processing of spray dried amorphous solid dispersions into minitablets designed for the paediatric population – A sustainable product development approachEuropean Journal of Pharmaceutical Sciences, 2024
- Question-based review for pharmaceutical development: An enhanced quality approachEuropean Journal of Pharmaceutics and Biopharmaceutics, 2023
- Amorphous solid dispersions: Utilization and challenges in preclinical drug development within AstraZenecaInternational Journal of Pharmaceutics, 2022
- Role of polymers in the physical and chemical stability of amorphous solid dispersion: A case study of carbamazepineEuropean Journal of Pharmaceutical Sciences, 2022
- ICH Q6A Specifications2017
- Downstream processing of polymer-based amorphous solid dispersions to generate tablet formulationsInternational Journal of Pharmaceutics, 2015
- Early drug development predictions of glass-forming ability and physical stability of drugsEuropean Journal of Pharmaceutical Sciences, 2013
- Assessing the performance of amorphous solid dispersionsJournal of Pharmaceutical Sciences, 2012